BACKGROUND: Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not been investigated. The aim of this study was to simulate and predict drug-drug interactions (DDIs) between these LA antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling. METHODS: The designed PBPK models were qualified (according to European Medicines Agency guidelines) against observed data for oral formulations of cabotegravir, rilpivirine, and rifampicin. Induction potential of rifampicin was also qualified by comparing the DDI between oral cabotegravir and oral rilpivirine with rifampicin. Qualified PBPK models were utilized for pharmacokinetic prediction of DDIs. RESULTS: PBPK models predicted a reduction in both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegravir of 41%-46% for the first maintenance dose coadministered with 600 mg once-daily oral rifampicin. Rilpivirine concentrations were predicted to decrease by 82% for both AUC0-28 days and Ctrough, 28th day following the first maintenance dose when coadministered with rifampicin. CONCLUSIONS: The developed PBPK models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA intramuscular formulations. According to these simulations, it is likely that coadministration of rifampicin with these LA formulations will result in subtherapeutic concentrations of both drugs.
BACKGROUND:Cabotegravir and rilpivirine are 2 long-acting (LA) antiretrovirals that can be administered intramuscularly; their interaction with rifampicin, a first-line antituberculosis agent, has not been investigated. The aim of this study was to simulate and predict drug-drug interactions (DDIs) between these LA antiretroviral agents and rifampicin using physiologically based pharmacokinetic (PBPK) modeling. METHODS: The designed PBPK models were qualified (according to European Medicines Agency guidelines) against observed data for oral formulations of cabotegravir, rilpivirine, and rifampicin. Induction potential of rifampicin was also qualified by comparing the DDI between oral cabotegravir and oral rilpivirine with rifampicin. Qualified PBPK models were utilized for pharmacokinetic prediction of DDIs. RESULTS: PBPK models predicted a reduction in both area under the curve (AUC0-28 days) and trough concentration (Ctrough, 28th day) of LA cabotegravir of 41%-46% for the first maintenance dose coadministered with 600 mg once-daily oral rifampicin. Rilpivirine concentrations were predicted to decrease by 82% for both AUC0-28 days and Ctrough, 28th day following the first maintenance dose when coadministered with rifampicin. CONCLUSIONS: The developed PBPK models predicted the theoretical effect of rifampicin on cabotegravir and rilpivirine LA intramuscular formulations. According to these simulations, it is likely that coadministration of rifampicin with these LA formulations will result in subtherapeutic concentrations of both drugs.
Authors: Owain Roberts; Rajith K R Rajoli; David J Back; Andrew Owen; Kristin M Darin; Courtney V Fletcher; Mohammed Lamorde; Kimberly K Scarsi; Marco Siccardi Journal: J Antimicrob Chemother Date: 2018-04-01 Impact factor: 5.790
Authors: David A Margolis; Juan Gonzalez-Garcia; Hans-Jürgen Stellbrink; Joseph J Eron; Yazdan Yazdanpanah; Daniel Podzamczer; Thomas Lutz; Jonathan B Angel; Gary J Richmond; Bonaventura Clotet; Felix Gutierrez; Louis Sloan; Marty St Clair; Miranda Murray; Susan L Ford; Joseph Mrus; Parul Patel; Herta Crauwels; Sandy K Griffith; Kenneth C Sutton; David Dorey; Kimberly Y Smith; Peter E Williams; William R Spreen Journal: Lancet Date: 2017-07-24 Impact factor: 79.321
Authors: Rajith K R Rajoli; Zach R Demkovich; Charles Flexner; Andrew Owen; Marco Siccardi Journal: Antimicrob Agents Chemother Date: 2020-07-22 Impact factor: 5.191
Authors: Behnaz Eshaghi; Josiane Fofana; Sarah B Nodder; Suryaram Gummuluru; Björn M Reinhard Journal: ACS Appl Mater Interfaces Date: 2022-01-07 Impact factor: 10.383
Authors: Kimberly K Scarsi; Joshua P Havens; Anthony T Podany; Sean N Avedissian; Courtney V Fletcher Journal: Drugs Date: 2020-11 Impact factor: 9.546
Authors: Rajith K R Rajoli; Henry Pertinez; Usman Arshad; Helen Box; Lee Tatham; Paul Curley; Megan Neary; Joanne Sharp; Neill J Liptrott; Anthony Valentijn; Christopher David; Steven P Rannard; Ghaith Aljayyoussi; Shaun H Pennington; Andrew Hill; Marta Boffito; Steve A Ward; Saye H Khoo; Patrick G Bray; Paul M O'Neill; W David Hong; Giancarlo A Biagini; Andrew Owen Journal: Br J Clin Pharmacol Date: 2020-12-01 Impact factor: 4.335